SODIUM ZIRCONIUM CYCLOSILICATE - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for sodium zirconium cyclosilicate and what is the scope of freedom to operate?
Sodium zirconium cyclosilicate
is the generic ingredient in one branded drug marketed by Astrazeneca and is included in one NDA. There are fourteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.Sodium zirconium cyclosilicate has one hundred and twenty patent family members in thirty-five countries.
Two suppliers are listed for this compound.
Summary for SODIUM ZIRCONIUM CYCLOSILICATE
International Patents: | 120 |
US Patents: | 14 |
Tradenames: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 2 |
Clinical Trials: | 27 |
Patent Applications: | 38 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for SODIUM ZIRCONIUM CYCLOSILICATE |
What excipients (inactive ingredients) are in SODIUM ZIRCONIUM CYCLOSILICATE? | SODIUM ZIRCONIUM CYCLOSILICATE excipients list |
DailyMed Link: | SODIUM ZIRCONIUM CYCLOSILICATE at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for SODIUM ZIRCONIUM CYCLOSILICATE
Generic Entry Date for SODIUM ZIRCONIUM CYCLOSILICATE*:
Constraining patent/regulatory exclusivity:
Dosage:
FOR SUSPENSION;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for SODIUM ZIRCONIUM CYCLOSILICATE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
NephroNet, Inc. | Phase 4 |
Michael Fu | Phase 2 |
St George's, University of London | Phase 3 |
Paragraph IV (Patent) Challenges for SODIUM ZIRCONIUM CYCLOSILICATE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
LOKELMA | for Oral Suspension | sodium zirconium cyclosilicate | 5 g/packet and 10 g/packet | 207078 | 5 | 2022-05-18 |
US Patents and Regulatory Information for SODIUM ZIRCONIUM CYCLOSILICATE
Expired US Patents for SODIUM ZIRCONIUM CYCLOSILICATE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Astrazeneca | LOKELMA | sodium zirconium cyclosilicate | FOR SUSPENSION;ORAL | 207078-001 | May 18, 2018 | ⤷ Try a Trial | ⤷ Try a Trial |
Astrazeneca | LOKELMA | sodium zirconium cyclosilicate | FOR SUSPENSION;ORAL | 207078-002 | May 18, 2018 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
EU/EMA Drug Approvals for SODIUM ZIRCONIUM CYCLOSILICATE
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
AstraZeneca AB | Lokelma | sodium zirconium cyclosilicate | EMEA/H/C/004029 Lokelma is indicated for the treatment of hyperkalaemia in adult patients. |
Authorised | no | no | no | 2018-03-22 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for SODIUM ZIRCONIUM CYCLOSILICATE
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Denmark | 2673237 | ⤷ Try a Trial | |
Australia | 2012214224 | Microporous zirconium silicate for the treatment of hyperkalemia | ⤷ Try a Trial |
Japan | 2016535754 | 高カリウム血症治療用細孔性ケイ酸ジルコニウム | ⤷ Try a Trial |
China | 109106725 | 用于治疗高钾血症的微孔性的硅酸锆 (MICROPOROUS ZIRCONIUM SILICATE FOR THE TREATMENT OF HYPERKALEMIA) | ⤷ Try a Trial |
Australia | 2013334776 | Microporous zirconium silicate for treating hyperkalemia | ⤷ Try a Trial |
European Patent Office | 2882444 | SILICATE DE ZIRCONIUM MICROPOREUX POUR LE TRAITEMENT DE L'HYPERKALIÉMIE (MICROPOROUS ZIRCONIUM SILICATE FOR TREATING HYPERKALEMIA) | ⤷ Try a Trial |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for SODIUM ZIRCONIUM CYCLOSILICATE
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2822954 | 18C1035 | France | ⤷ Try a Trial | PRODUCT NAME: BICTEGRAVIR OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE,EN PARTICULIER BICTEGRAVIR DE SODIUM; REGISTRATION NO/DATE: EU/1/18/1289 20180625 |
0957929 | SPC/GB06/021 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: PEGAPTANIB, PREFERABLY IN THE FORM OF ITS SODIUM SALT; REGISTERED: UK EU/1/05/325/001 20060201 |
2673237 | 122019000036 | Germany | ⤷ Try a Trial | PRODUCT NAME: NATRIUMZIRCONIUMCYCLOSILICAT; REGISTRATION NO/DATE: EU/1/17/1173 20180322 |
1713823 | 1490064-1 | Sweden | ⤷ Try a Trial | PRODUCT NAME: SIMEPREVIR, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING SIMEPREVIR SODIUM; REG. NO/DATE: EU/1/14/924 20140516 |
2340828 | LUC00195 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: SACUBITRIL ET VALSARTAN, SOUS FORME DE COMPLEXE DE SEL DE SODIUM SACUBITRIL VALSARTAN, C'EST-A-DIRE (((S)-N-VALERYL-N-((2'-(1H-TETRAZOLE-5-YL)-BIPHENYL-4-YL)-METHYL)-VALINE) ((2R,4S)-5-BIPHENYL-4-YL-4-(3-CARBOXY-PROPIONYLAMINO)-2-METHYL-ESTER ETHYLIQUE D'ACIDE PENTANOIQUE))NA3 X H2O, DANS LEQUEL X EST 0 A 3; AUTHORISATION NUMBER AND DATE: EU/1/15/1058 20151123 |
1758590 | 2017C/063 | Belgium | ⤷ Try a Trial | PRODUCT NAME: SEL DE SODIUM D'ACIDE DESOXYCHOLIQUE; AUTHORISATION NUMBER AND DATE: SE/H/1547/01/DC 20170612 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |